1

Table 1 An overview of key clinical trials of afatinib in lung cancer Yu, H. A. & Pao, W. (2013) Afatinib—new therapy option for EGFR-mutant lung cancer Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2013.154

Table 1 An overview of key clinical trials of afatinib in lung cancer

Download PPT Report

Upload
rhea-oneil
View
25
Download
0

Embed Size (px)

DESCRIPTION

Table 1 An overview of key clinical trials of afatinib in lung cancer. Yu, H. A. & Pao, W. ( 2013) Afatinib—new therapy option for EGFR-mutant lung cancer Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2013.154. - PowerPoint PPT Presentation

Citation preview

Page 1: Table 1 An overview of key clinical trials of afatinib in lung cancer

Table 1 An overview of key clinical trials of afatinib in lung cancer

Yu, H. A. & Pao, W. (2013) Afatinib—new therapy option for EGFR-mutant lung cancerNat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2013.154

e-print - Mosby · Asian patients (13–15%).16 LUX-Lung 3 was the ﬁ rst global trial to compare an irreversible ErbB family blocker (afatinib) with chemotherapy and the ﬁ rst

e-print - Mosby · Asian patients (13–15%).16 LUX-Lung 3 was the ﬁ rst global trial to compare an irreversible ErbB family blocker (afatinib) with chemotherapy and the ﬁ rst

Documents

Afatinib delays …enews.mims.com/landingpages/onco/pdf/Oncology_Tribune_July_2012_SG.pdfprostate cancer screening recommendations ... [ASCO 2012; abstract LBA7500] ... creased with

Afatinib delays …enews.mims.com/landingpages/onco/pdf/Oncology_Tribune_July_2012_SG.pdfprostate cancer screening recommendations ... [ASCO 2012; abstract LBA7500] ... creased with

Documents

July 10, 2019 Quality Assurance Section CTEP, DCT, NCI ...Afatinib dimaleate (hereafter, referred to as afatinib) is a potent and selective, oral irreversible inhibitor of ErbB family

July 10, 2019 Quality Assurance Section CTEP, DCT, NCI ...Afatinib dimaleate (hereafter, referred to as afatinib) is a potent and selective, oral irreversible inhibitor of ErbB family

Documents

LUX-Lung 7 infographicV9 - Boehringer Ingelheim · Afatinib signiﬁcantly increased compared with 4% of patients treated ... ECOG PS 0–1 1 1 N=319 RANDOMISED n=160 ... LUX-LUNG

LUX-Lung 7 infographicV9 - Boehringer Ingelheim · Afatinib signiﬁcantly increased compared with 4% of patients treated ... ECOG PS 0–1 1 1 N=319 RANDOMISED n=160 ... LUX-LUNG

Documents

Treatment Options for Patients With Brain Metastasis: A ......Patients with brain mets Patients without brain mets With brain mets Afatinib Chemo P value LUX-Lung 3 70% 20% 0.0058

Treatment Options for Patients With Brain Metastasis: A ......Patients with brain mets Patients without brain mets With brain mets Afatinib Chemo P value LUX-Lung 3 70% 20% 0.0058

Documents

Afatinib versus methotrexate as second-line treatment for ... · Afatinib versus methotrexate as second-line treatment for patients with R/M HNSCC progressing on or after platinum-based

Afatinib versus methotrexate as second-line treatment for ... · Afatinib versus methotrexate as second-line treatment for patients with R/M HNSCC progressing on or after platinum-based

Documents

ARDS TRIALS UPDATE 2014 - American Lung Association

ARDS TRIALS UPDATE 2014 - American Lung Association

Documents

NCI Resources for Biobanking...– Emerging clinical biomarker assays in clinical trials – New diagnostics challenges • FNA, Core Biopsies, Lung Aspirates for Molecular Testing

NCI Resources for Biobanking...– Emerging clinical biomarker assays in clinical trials – New diagnostics challenges • FNA, Core Biopsies, Lung Aspirates for Molecular Testing

Documents

Lung Cancer Screening: Clinical Trials, Screening ... · International Early Lung Cancer Action Program Investigators. The Impact of the Regimen of Screening on Lung Cancer Cure:

Lung Cancer Screening: Clinical Trials, Screening ... · International Early Lung Cancer Action Program Investigators. The Impact of the Regimen of Screening on Lung Cancer Cure:

Documents

IV INTERNATIONAL MEETING OF YOUNG ONCOLOGIST ......Kanarev 15.40 – 15.55 New alternatives in lung cancer treatment: Introducing afatinib - N. Chilingirova 15.55 – 16.10 Endovascular

IV INTERNATIONAL MEETING OF YOUNG ONCOLOGIST ......Kanarev 15.40 – 15.55 New alternatives in lung cancer treatment: Introducing afatinib - N. Chilingirova 15.55 – 16.10 Endovascular

Documents

Clinical trials in idiopathic pulmonary fibrosis: update ... · Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrosing interstitial lung disease of unknown cause

Clinical trials in idiopathic pulmonary fibrosis: update ... · Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrosing interstitial lung disease of unknown cause

Documents

Afatinib for the treatment of advanced non-small-cell lung

Afatinib for the treatment of advanced non-small-cell lung

Documents

First-line afatinib vs gefitinib for patients with EGFR ... · ORIGINAL ARTICLE - CLINICAL ONCOLOGY First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC

First-line afatinib vs gefitinib for patients with EGFR ... · ORIGINAL ARTICLE - CLINICAL ONCOLOGY First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC

Documents

MicroRNA and lung cancer Gabriella Sozzi. Lung Cancer Screening by LDCT : critical issues Recent clinical trials results (DANTE, 2009, DLCST, 2012, MILD

MicroRNA and lung cancer Gabriella Sozzi. Lung Cancer Screening by LDCT : critical issues Recent clinical trials results (DANTE, 2009, DLCST, 2012, MILD

Documents

Pragmatic Trials: how early in drug development? Salford Lung … · RF/RESP/0006/15(1) January 2015 Salford Lung Study Ambition ... sleep quality, self management of disease, disease

Pragmatic Trials: how early in drug development? Salford Lung … · RF/RESP/0006/15(1) January 2015 Salford Lung Study Ambition ... sleep quality, self management of disease, disease

Documents

LUNG CANCER CLINICAL TRIALS - GO2 Foundation for Lung Cancer€¦ · CLINICAL TRIALS Phase I clinical trials test the new treatment in only a few people (less than 50) and usually

LUNG CANCER CLINICAL TRIALS - GO2 Foundation for Lung Cancer€¦ · CLINICAL TRIALS Phase I clinical trials test the new treatment in only a few people (less than 50) and usually

Documents

Real-World Data and Randomised Controlled Trials: The Salford … · 2020-02-28 · REVIEW Real-World Data and Randomised Controlled Trials: The Salford Lung Study David A. Leather

Real-World Data and Randomised Controlled Trials: The Salford … · 2020-02-28 · REVIEW Real-World Data and Randomised Controlled Trials: The Salford Lung Study David A. Leather

Documents

Afatinib followed by osimertinib in patients with EGFR ... · Afatinib followed by osimertinib in patients with EGFR mutation-positive (EGFRm+) advanced NSCLC: updated data from the

Afatinib followed by osimertinib in patients with EGFR ... · Afatinib followed by osimertinib in patients with EGFR mutation-positive (EGFRm+) advanced NSCLC: updated data from the

Documents

Program Announcement Lung Cancer Research …Clinical Trials: The CEA will support clinical trials encompassing Phase 0, Phase I, or pilot Phase II for drug or drug combinations, Class

Program Announcement Lung Cancer Research …Clinical Trials: The CEA will support clinical trials encompassing Phase 0, Phase I, or pilot Phase II for drug or drug combinations, Class

Documents

Best of ASCO 2012 Lung Cancer - kanser.orgkanser.org/saglik/upload/malign_pdf2/Lung_Cancer#FULDEN_YUMUK.pdf · afatinib vs cisplatin/pemetrexed as 1st-line treatment for patients

Best of ASCO 2012 Lung Cancer - kanser.orgkanser.org/saglik/upload/malign_pdf2/Lung_Cancer#FULDEN_YUMUK.pdf · afatinib vs cisplatin/pemetrexed as 1st-line treatment for patients

Documents

Afatinib, erlotinib, gefitinib, krizotinib i pemetreksed u liječenju

Afatinib, erlotinib, gefitinib, krizotinib i pemetreksed u liječenju

Documents

Afatinib Is a New Therapeutic Approach in Chordoma with a ... · Small Molecule Therapeutics Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR

Afatinib Is a New Therapeutic Approach in Chordoma with a ... · Small Molecule Therapeutics Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR

Documents

Chemotherapy in Non-Small Cell Lung Cancer: An Update · Protocol D Chemotherapy in Non-Small Cell Lung Cancer: An Update A meta-analysis of randomised trials using individual patient

Chemotherapy in Non-Small Cell Lung Cancer: An Update · Protocol D Chemotherapy in Non-Small Cell Lung Cancer: An Update A meta-analysis of randomised trials using individual patient

Documents

Australasian Lung Trials Group 2018 Symposium in Lung Cancer · Australasian Lung Trials Group 2018 Symposium in Lung Cancer Proudly sponsored by: ... a rare lung cancer, advocacy

Australasian Lung Trials Group 2018 Symposium in Lung Cancer · Australasian Lung Trials Group 2018 Symposium in Lung Cancer Proudly sponsored by: ... a rare lung cancer, advocacy

Documents

VLV FRQW¶G &DVH UHSRUW RYHUYLHZ · Background: afatinib in multifocal GBM • Afatinib is an ErbB family blocker that irreversibly binds and inhibits the activity of all ErbB family

VLV FRQW¶G &DVH UHSRUW RYHUYLHZ · Background: afatinib in multifocal GBM • Afatinib is an ErbB family blocker that irreversibly binds and inhibits the activity of all ErbB family

Documents

The Small Cell Lung Cancer Working Group Clinical Trials ... · PDF fileSmall Cell Lung Cancer . Seizing on Opportunities to Translate Recent Research into the Clinic for New Diagnostics

The Small Cell Lung Cancer Working Group Clinical Trials ... · PDF fileSmall Cell Lung Cancer . Seizing on Opportunities to Translate Recent Research into the Clinic for New Diagnostics

Documents

Are EGFR TKIs Treatment Options for NSCLC With Brain ... · Patients With Brain Mets Patients Without Brain Mets With Brain Mets Afatinib Chemo P value LUX-Lung 3 70% 20% 0.0058 LUX-Lung

Are EGFR TKIs Treatment Options for NSCLC With Brain ... · Patients With Brain Mets Patients Without Brain Mets With Brain Mets Afatinib Chemo P value LUX-Lung 3 70% 20% 0.0058 LUX-Lung

Documents

Early Lung Cancer · 2016. 10. 28. · e – Include biomarker analysis in lung cancer screening trials. f – Support an infrastructure, such as EDRN, for validation trials for biomarker

Early Lung Cancer · 2016. 10. 28. · e – Include biomarker analysis in lung cancer screening trials. f – Support an infrastructure, such as EDRN, for validation trials for biomarker

Documents

Update on Therapies: Clinical Trials Timothy PM Whelan Assistant Professor of Medicine Medical Director, Interstitial Lung Disease Program University of

Update on Therapies: Clinical Trials Timothy PM Whelan Assistant Professor of Medicine Medical Director, Interstitial Lung Disease Program University of

Documents

Clinical Activity of Afatinib in Patients With Non—Small ... · lung cancer are created equal: perspectives for individualized treatment strategy. Cancer Sci 2016; 107:1179-86

Clinical Activity of Afatinib in Patients With Non—Small ... · lung cancer are created equal: perspectives for individualized treatment strategy. Cancer Sci 2016; 107:1179-86

Documents